Parallax Volatility Advisers
DNLI icon

Parallax Volatility Advisers’s Denali Therapeutics DNLI Stock Holding History

Parallax Volatility Advisers’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-26,777
Closed -$1.53M – 3115
2021
Q1 		$1.53M Buy
+26,777
New +$1.79M ﹤0.01% 1875
2018
Q4 		– Sell
-23
Closed -$1K – 3061
2018
Q3 		$1K Buy
+23
New +$380 ﹤0.01% 2464

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallax Volatility Advisers's DNLI Position: Q2 2021 in Review

Parallax Volatility Advisers sold out of Denali Therapeutics (DNLI) in Q2 2021, closing a stake of 26,777 shares — an estimated $1.53M sold.

Parallax Volatility Advisers first reported a position in DNLI in Q3 2018 and held it in 2 quarters. The position peaked at $1.53M in Q1 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

  • Parallax Volatility Advisers reported no remaining Denali Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 26,777 Denali Therapeutics shares in Q2 2021, an estimated $1.53M.
  • Parallax Volatility Advisers first reported a position in Denali Therapeutics in Q3 2018 and held it in 2 quarters.
  • Parallax Volatility Advisers's Denali Therapeutics position peaked at $1.53M in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on Parallax Volatility Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.